More Than a Test Kit
Unibioscience is developing a platform infrastructure for recurring risk monitoring, structured follow-up, dashboard-based health insights and scalable access across consumer, clinical and B2B channels.
Recurring Risk Monitoring
Transitioning from one-off screening to continuous, longitudinal tracking of biological signals.
Platform Subscription
Offering recurring subscription models for professional dashboards and data-driven monitoring services.
Structured Follow-Up
Providing healthcare professionals with organized reports and trend data to guide clinical decisions.
B2B Partnerships
Collaborating with diagnostic manufacturers and digital health partners to expand the ecosystem.
Scalable Access
Building a scalable infrastructure that supports accessible early risk awareness for diverse populations.
Data-Driven Insights
Generating structured risk insights and personalized recommendations based on AI-supported analysis.
The Unibioscience platform is currently in clinical development and is not approved for commercial use. It is intended to support early risk awareness and does not provide a definitive diagnosis. Any elevated-risk result should be confirmed through clinical evaluation and laboratory-based testing.
Strategic Business Model
Unibioscience is building a scalable platform infrastructure for recurring risk monitoring, structured follow-up, and data-driven health insights.
Single Biomarker Tests
Initial revenue from individual biomarker test kits targeting specific cancer risk areas.
Professional Dashboards
Secure, institutional-grade data management and dashboard solutions for clinical teams.
Platform Subscription
Recurring revenue from subscription models for continuous monitoring and AI risk insights.
Data-Driven Services
Advanced monitoring services and risk analytics for institutional and public health partners.
B2B Partnerships
Strategic collaborations with healthcare providers and diagnostic manufacturers for integration.
Diagnostic Manufacturing
Future revenue from multiplex test development and manufacturing partnerships.
The Unibioscience platform is currently in clinical development and is not approved for commercial use. It is intended to support early risk awareness and does not provide a definitive diagnosis. Any elevated-risk result should be confirmed through clinical evaluation and laboratory-based testing.
Use of Funds — €6–8M
A strategic allocation to accelerate the transition from laboratory-stage validation to clinical readiness.
Clinical Validation (40%)
Investment in prospective clinical studies to validate analytical performance and clinical relevance in the intended population.
€2.4–3.2M
Regulatory Development (25%)
Establishing the IVDR pathway through performance evaluation plans, risk management files, and quality management system (QMS) implementation.
€1.5–2.0M
AI Platform (20%)
Development of the digital intelligence layer, including longitudinal risk scoring algorithms and secure dashboard infrastructure.
€1.2–1.6M
Team Expansion (10%)
Recruitment of clinical researchers, data scientists, and regulatory experts to support the scaling of the Belgian platform.
€0.6–0.8M
Market Access (5%)
Commercial preparation, including strategic partnerships, B2B channel development, and regional market entry strategies.
€0.3–0.4M
The Unibioscience platform is currently in clinical development and is not approved for commercial use. It is intended to support early risk awareness and does not provide a definitive diagnosis. Any elevated-risk result should be confirmed through clinical evaluation and laboratory-based testing.
Partner With Europe’s Early Risk Monitoring Infrastructure
Unibioscience is building a scalable platform combining biomarker testing, smartphone interpretation and AI-supported longitudinal risk analytics. We invite qualified investors, scientific reviewers and strategic partners to join our clinical development journey.